证券日报网讯 10月20日晚间，信立泰发布公告称，公司收到子公司美国SalubrisBiotherapeutics，Inc.的 通知，其在2025年欧洲肿瘤内科学会年会（ESMO）展示了JK06在I/II期临床试验中的部分剂量递增数 据。初步的数据显示，JK06在包括非小细胞肺癌（NSCLC）和乳腺癌在内的不可切除的局部晚期或转 移性肿瘤患者中，展现出良好的安全性和疗效。 （文章来源：证券日报） ...

格隆汇10月20日丨信立泰(002294.SZ)公布，收到子公司美国SalubrisBiotherapeutics,Inc.（下 称"SalubrisBio"）的通知，其在2025年欧洲肿瘤内科学会年会（ESMO）展示了JK06在I/II期临床试验中 的部分剂量递增数据。初步的数据显示，JK06在包括非小细胞肺癌（NSCLC）和乳腺癌在内的不可切 除的局部晚期或转移性肿瘤患者中，展现出良好的安全性和疗效。 ESMO会议上报告的数据，涵盖了JK06在欧洲（部分国家）入组的34例晚期复发性/难治性实体瘤患 者。所有患者均为接受肿瘤标准治疗方案失败后入组，其中83%曾接受过三线或以上治疗，59%曾接受 过四线或以上治疗。在剂量递增阶段入组的患者按每三周（Q3W）一次的频率接受JK06治疗，覆盖五 个剂量水平（1.5-8.0mg/kg）。其中，29例患者经过肿瘤临床疗效评估，并获得关键疗效性数据。 ...

ESMO会议上报告的数据，涵盖了JK06在欧洲（部分国家）入组的34例晚期复发性/难治性实体瘤患 者。所有患者均为接受肿瘤标准治疗方案失败后入组，其中83%曾接受过三线或以上治疗，59%曾接受 过四线或以上治疗。在剂量递增阶段入组的患者按每三周（Q3W）一次的频率接受JK06治疗，覆盖五 个剂量水平（1.5-8.0mg/kg）。其中，29例患者经过肿瘤临床疗效评估，并获得关键疗效性数据。 格隆汇10月20日丨信立泰(002294.SZ)公布，收到子公司美国SalubrisBiotherapeutics,Inc.（下 称"SalubrisBio"）的通知，其在2025年欧洲肿瘤内科学会年会（ESMO）展示了JK06在I/II期临床试验中 的部分剂量递增数据。初步的数据显示，JK06在包括非小细胞肺癌（NSCLC）和乳腺癌在内的不可切 除的局部晚期或转移性肿瘤患者中，展现出良好的安全性和疗效。 ...

证券代码：002294 证券简称：信立泰 编号：2025-054 深圳信立泰药业股份有限公司 关于 JK06 境外临床试验进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳信立泰药业股份有限公司（下称"公司"）收到子公司美国 Salubris Biotherapeutics, Inc.（下称"Salubris Bio"）的通知，其在 2025 年欧洲肿瘤内科 学会年会（ESMO）展示了 JK06 在 I/II 期临床试验中的部分剂量递增数据。初 步的数据显示，JK06 在包括非小细胞肺癌（NSCLC）和乳腺癌在内的不可切除 的局部晚期或转移性肿瘤患者中，展现出良好的安全性和疗效。现就相关信息公 告如下： 一、JK06 临床试验进展 （3） 在 7 例乳腺癌患者中，1 例经确认达到部分缓解（PR），缓解时间维 持 18 周。 （4） 达到部分缓解（PR）的剂量组，分别为 3.0 mg/kg（1 例 NSCLC）、 4.5 mg/kg（3 例 NSCLC 和 1 例乳腺癌）、6.0 mg/kg（1 例 NSCLC）。 2、在安全性和耐受性方面， ...

Core Viewpoint - The market experienced a correction last week, but certain stocks within the brand index showed resilience, indicating potential investment opportunities in sectors like electronics, new energy, new consumption, and real estate as uncertainties ease [1][4]. Market Performance - The market indices saw declines: Shanghai Composite Index down 1.47%, Shenzhen Component down 4.99%, ChiNext down 5.71%, and CSI 300 down 2.22%. The brand index fell 3.58% to 1956.62 points [2]. - Notable gainers in the brand index included Shanghai Jahwa up 9.42%, Changbai Mountain up 7.19%, and Darentang up 5.34%. Other stocks like Luzhou Laojiao and Yiling Pharmaceutical also saw gains exceeding 4% [2]. Stock Performance Since H2 - Since the beginning of the second half of the year, Zhongji Xuchuang has surged 156.40%, leading the gains, followed by Sunshine Power at 114.27%. Other significant performers include Lanke Technology and Yiwei Lithium Energy, both up over 60% [3]. Market Outlook - Looking ahead, the market is expected to maintain upward momentum as uncertainties gradually diminish. Liquidity is anticipated to remain supportive, with domestic interest rates low and overseas liquidity remaining loose, encouraging investment in Chinese equity assets [4][5]. - The current market environment is characterized by a shift in investment styles, with a focus on sectors that offer higher investment certainty, particularly in electronics, new energy, new consumption, and real estate [5].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [3] Core Viewpoints - The report emphasizes that the fourth quarter is expected to see a rebound in innovative drugs, driven by a concentration of business development (BD) activities and upcoming events such as the ESMO conference and medical insurance negotiations [4][16] - The Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs significantly opening new growth avenues for Chinese pharmaceutical companies [16][35] - The report suggests that the demand for healthcare will continue to rise due to an aging population, and the payment side is also expected to grow steadily, supported by the development of a multi-tiered payment system [35] Summary by Sections 1. BD + ESMO - The number of license-out transactions in China has been increasing, with 135 transactions occurring from January 1, 2025, to October 17, 2025, totaling $10.2996 billion [8][9] - The report highlights that the international pharmaceutical industry recognizes the value of Chinese innovative drug assets, which are characterized by high quality and low cost [8][9] - The ESMO conference will showcase 23 studies led by Chinese scholars, indicating a significant increase in international recognition of Chinese innovation [12][13] 2. Industry Perspective - The report maintains that innovative drugs will remain the main focus for the year, with attention on manufacturing, overseas expansion, and aging-related consumption [16][35] - The pharmaceutical index has shown a decline of 2.48% in the past week, but an increase of 18.85% year-to-date, indicating a mixed performance [16] - The report lists several companies to watch, including innovative drug manufacturers and those involved in the supply chain [38]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 深圳信立泰药业股份有限公司（下称"公司"）于近日接到公司控股股东信立泰药业有限公司（下称"香 港信立泰"）的通知，获悉其将所持有的本公司部分股份解除质押。具体情况如下： 一、股东股份解除质押基本情况 上述股份解除质押相关手续已在中国证券登记结算有限责任公司办理完成。 2、股东股份累计质押情况 截至本公告披露日，上述股东所持质押股份情况如下： ■ 二、其他说明 1、本次解除质押基本情况 1、信立泰药业有限公司所持有的本公司股份不存在被冻结、标记、拍卖或设定信托的情形。 2、信立泰药业有限公司不存在非经营性资金占用、违规担保等侵害上市公司利益的情形。 3、截至本公告披露日，信立泰药业有限公司持有本公司股份63,527.938万股，占公司股份总数的 56.99%，本次股份解除质押办理完毕后，其持有的累计处于被质押状态的股份数量为9,700万股，均为 无限售条件流通股，占其持股总数的15.27%，占公司股份总数的8.70%。 ■ 注：以上数字计算如有差异，或本公告中有关比 ...

证券日报网讯 10月15日晚间，信立泰发布公告称，公司于近日接到公司控股股东信立泰药业有限公司 的通知，获悉其将所持有的本公司部分股份解除质押，解除质押股份数量为1，700.00万股。 （文章来源：证券日报） ...

Core Viewpoint - The announcement regarding the partial pledge release of shares by the controlling shareholder of Xinlitai has attracted market attention, indicating a positive signal for investor confidence in the company [1]. Summary by Relevant Sections Release of Pledge - Xinlitai Pharmaceutical Co., Ltd. (Hong Kong Xinlitai) has released a total of 1,700,000 shares from pledge, which accounts for 2.68% of its holdings and 1.52% of the company's total share capital [2]. - The released shares include 1,100,000 shares (1.73% of its holdings) and 600,000 shares (0.94% of its holdings), with the pledges initiated on June 13, 2018, and October 11, 2019, respectively, and set to be released by October 14, 2025 [2]. Pledged Shares Situation - As of the announcement date, Xinlitai Pharmaceutical holds 63,527,938 shares, representing 56.99% of the company, with 9,700,000 shares currently under pledge, which is 15.27% of its total holdings and 8.70% of the company's total share capital [3]. - There are no frozen, marked, auctioned, or trust-set shares, nor any non-operational fund occupation or illegal guarantees that could harm the interests of the listed company [3]. Financial Health and Control - Xinlitai Pharmaceutical has a good credit status and repayment capability, indicating that the risks associated with pledged shares are manageable [3]. - The pledge of shares will not lead to any change in the actual control of the company and will not affect its production, operation, or governance [3].

北京商报讯（记者 丁宁）10月15日晚间，信立泰（002294）发布公告称，公司收到国家药品监督管理 局核准签发的受理通知书，公司自主研发的创新小分子药物SAL0137片（项目代码：SAL0137）临床试 验申请获得受理。 信立泰表示，SAL0137是公司研发的具有自主知识产权的口服小分子药物，公司本次提交的申请为 SAL0137用于治疗脂蛋白（a）增高的临床试验申请。 ...